[1] ZENG Y H, YANG Y, WANG J, et al. The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials[J]. Osteoporos Int, 2024, 35(11): 1897-1907.
[2] NARAYANASAMY M, BISHOP S, SAHOTA O, et al. Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults[J]. Age Ageing, 2022, 51(11): afac255. doi:  10.1093/ageing/afac255
[3] CURTIS J R, YUN H F, MATTHEWS R, et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population[J]. Arthritis Care Res(Hoboken), 2012, 64(7): 1054-1060. doi:  10.1002/acr.21638
[4] MODI A, SAJJAN S, INSINGA R, et al. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years[J]. Osteoporos Int, 2017, 28(4): 1355-1363.
[5] LI C, LU K, SHI Q, et al. Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms[J]. Ther Adv Chronic Dis, 2022, 13: 20406223221114214.
[6] 李萍, 李潇潇, 赵荣生. 骨质疏松患者首次静脉滴注唑来膦酸致急性期反应危险因素的Meta分析[J]. 药物不良反应杂志, 2017, 19(6): 425-431.
[7] REID I R, GAMBLE G D, MESENBRINK P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid[J]. J Clin Endocrinol Metab, 2010, 95(9): 4380-4387.
[8] THIÉBAUD D, SAUTY A, BURCKHARDT P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates[J]. Calcif Tissue Int, 1997, 61(5): 386-392.
[9] ROELOFS A J, JAUHIAINEN M, MÖNKKÖNEN H, et al. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP[J]. Br J Haematol, 2009, 144(2): 245-250.
[10] 安艳芳, 方立. 汉防己甲素联合阿仑膦酸钠治疗类风湿性关节炎合并骨质疏松疗效观察[J]. 药物流行病学杂志, 2019, 28(2): 103-106.
[11] SONG M Y, WANG J X, SUN Y L, et al. Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages[J]. Acta Pharmacol Sin, 2022, 43(5): 1274-1284.
[12] GAO P, RAO Z W, LI M, et al. Tetrandrine represses inflammation and attenuates osteoarthritis by selective inhibition of COX-2[J]. Curr Med Sci, 2023, 43(3): 505-513.
[13] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14): 1671-1691.
[14] DICUONZO G, VINCENZI B, SANTINI D, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6[J]. J Interferon Cytokine Res, 2003, 23(11): 649-654.
[15] WARK J D, BENSEN W, RECKNOR C, et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 Mg[J]. Osteoporos Int, 2012, 23(2): 503-512.
[16] CHEN C H, YEAP E K, HSU C H, et al. Novel combined pharmacological strategy to alleviate acute phase response following zoledronic acid treatment[J]. Arch Osteoporos, 2024, 19(1): 97.
[17] LU K, SHI Q, GONG Y Q, et al. Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate[J]. Osteoporos Int, 2022, 33(11): 2381-2396.
[18] LU K, SHI Q, GONG Y Q, et al. Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients[J]. Front Endocrinol(Lausanne), 2022, 13: 991913.
[19] CROTTI C, WATTS N B, DE SANTIS M, et al. Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin d and previous oral bisphosphonate therapy[J]. Endocr Pract, 2018, 24(5): 405-410.
[20] MERLOTTI D, RENDINA D, MUSCARIELLO R, et al. Preventive role of vitamin D supplementation for acute phase reaction after bisphosphonate infusion in Paget’s disease[J]. J Clin Endocrinol Metab, 2020, 105(3): dgz138.
[21] BERNICKE B, ENGELBOGEN N, KLEIN K, et al. Analysis of the seasonal fluctuation of γδ T cells and its potential relation with vitamin D3[J]. Cells, 2022, 11(9): 1460.
[22] DE SANTIS M, CAVACIOCCHI F, CERIBELLI A, et al. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction[J]. Lupus, 2015, 24(4-5): 442-447.